Source: Kapitales Research

Highlights:

• CSL Limited slumped as much as 20% after cutting FY26 guidance and flagging fresh impairments
• The biotech giant now expects FY26 revenue of around US$15.2 billion and NPATA of about US$3.1 billion
• Investors reacted sharply to weaker US immunoglobulin sales, China pricing pressure, and a further erosion in confidence

Shares of CSL Limited (ASX: CSL) were hammered on Monday, placing the healthcare heavyweight on track for its worst trading session on record after management unveiled a major earnings downgrade and billions of dollars in fresh asset impairments. CSL shares were down 16.7% to AU$99.86 in afternoon trade after earlier tumbling more than 20% to a decade low of AU$93.63. The sell-off wiped roughly AU$10 billion from the company’s market capitalisation as investors responded to weaker growth expectations and mounting concerns around execution. The stock has now fallen more than 42% since the start of 2026 and around 65% from its August 2025 highs above AU$270.

Healthcare Sector Tumbles 6.95% as CSL Sparks Heavy Selling

The healthcare sector plunged 6.95% as investors rushed to exit CSL Limited following the company’s sharp earnings downgrade and multi-billion-dollar impairment update. Given CSL’s heavyweight position on the ASX, the stock’s near-record decline dragged the broader healthcare index sharply lower and weighed heavily on overall market sentiment.

CSL cuts FY26 outlook

CSL said it now expects FY26 revenue of approximately US$15.2 billion and NPATA of around US$3.1 billion on a constant currency basis, excluding restructuring and impairment costs. The downgrade follows softer-than-expected conditions across several key business segments. Management said reported US immunoglobulin revenue would be impacted by inventory normalisation, creating an estimated US$300 million hit to revenue. Meanwhile, the company’s albumin business in China is facing declining market values despite stable volumes and rising market share, resulting in another estimated US$200 million revenue impact. CSL also cited the impact of Middle East conflict disruptions, slower-than-expected growth from HEMGENIX, and heightened competition in its iron business as additional headwinds worth about US$150 million.

The revised outlook compares with FY25 revenue of US$15.6 billion and profit of US$3.3 billion. Fresh impairments deepen investor concerns In another blow to sentiment, CSL announced it expects to recognise an additional approximately US$5 billion in non-cash pre-tax impairments across FY26 and FY27, on top of the US$1.5 billion already recognised at its first-half FY26 results.

The write-downs are largely tied to CSL Vifor’s intangible assets, including sections of its product portfolio, along with certain property, plant and equipment assets that are not being fully utilised. The company added that the proposed charges are still undergoing further assessment and remain subject to external audit and board approval.

Interim CEO outlines turnaround strategy

Interim chief executive Gordon Naylor said his 90-day review found CSL’s growth initiatives were progressing, although the financial benefits would take longer than previously anticipated to materialise.

Naylor pointed to operational simplification, cost reductions, commercial execution improvements, and transformation initiatives already underway. CSL said its transformation program is expected to deliver annual cost savings of roughly US$500 million to US$550 million by FY28.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au